Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Cited by (1,007)

Items 601–700 of 1,007

1. Generation and persistence of S1 IgG and neutralizing antibodies in post-COVID-19 patients
   Oscar Guzmán-Martínez, Kathia Guardado, Miguel Varela Cardoso, Alejandro Trujillo-Rivera, Antonio Marı́n-Hernández, María Cristina Ortiz León, Iván Gómez-Ñañez, Michelle Gutiérrez, Rafaela Espinosa, Clara Luz Sampieri et al. · 2021 · Infection
2. Durability of Antibody Responses to SARS-CoV-2 Infection and Its Relationship to Disease Severity Assessed Using a Commercially Available Assay
   Alanoud Alshami, Rabab A. Al Attas, Hadeel Anan, Aroub Al Maghrabi, Salim S. Ghandorah, Amani Mohammed, Abdulbary Ali Alhalimi, Jumana Mansour Al-Jishi, Hadi Alqahtani · 2021 · Frontiers in Microbiology
3. Evolution of anti-SARS-CoV-2 immune response in a cohort of French healthcare workers followed for 7 months
   B. Pilmis, Iheb Elkaibi, Gauthier Péan de Ponfilly, H. Daikha, A. Bouzid, Amélie Guihot, N. Castreau, Pauline Pradère, Hela Ketatni, A. Mondragon et al. · 2022 · Infectious Diseases Now
4. Detection of Neutralizing Antibodies against SARS-CoV-2 Post-Vaccination in Health Care Workers of a Large Tertiary Hospital in Spain by Using a Rapid Test LFIC and sVNT-ELISA
   José Tuells, Mónica Parra-Grande, Francisco J. Santos-Calle, Ana C. Montagud, Cecilia M. Egoavil, Celia García-Rivera, Pablo Caballero, Eva María Gabaldón Bravo, Juan Carlos Rodrı́guez, José Antonio Hurtado Sánchez · 2022 · Vaccines
5. Features of humoral immunity after COVID-19
   E. V. Semenova, V. V. Pavliuk, M. A. Uvarova, А. В. Иванов · 2022 · Medical Immunology (Russia)
6. Selective Detection and Ultrasensitive Quantification of SARS-CoV-2 IgG Antibodies in Clinical Plasma Samples Using Epitope-Modified Nanoplasmonic Biosensing Platforms
   Adrianna N. Masterson, Rajesh Sardar · 2022 · ACS Applied Materials & Interfaces
7. The Effect of Vaccine Type and SARS-CoV-2 Lineage on Commercial SARS-CoV-2 Serologic and Pseudotype Neutralization Assays in mRNA Vaccine Recipients
   Nicole V. Tolan, A. Sherman, Guo-Hai Zhou, K. Nabel, M. Desjardins, Stacy E. F. Melanson, S. Kanjilal, S. Moheed, John A Kupelian, R. Kaufman et al. · 2022 · Microbiology spectrum
8. Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
   Sharon Lynn Walmsley, Majid Nabipoor, Freda Qi, Leif Erik Lovblom, Rizani Ravindran, Karen Colwill, Roya Monica Dayam, Tulunay R. Tursun, Amanda Silva, Anne‐Claude Gingras et al. · 2024 · Vaccines
9. Effective virus-neutralizing activities in antisera from the first wave of survivors of severe COVID-19
   Yang Han, Peipei Liu, Yang Qiu, Jie Zhou, Ying Liu, Xujuan Hu, Qingyu Yang, Rui Huang, Xinyue Wen, Hao Song et al. · 2021 · JCI Insight
10. Seroprevalence of anti-SARS-CoV-2 IgG in asymptomatic and pauci-symptomatic people over a 5 month survey in Argentina
    Luz Rodeles, Luz María Peverengo, Romina Benítez, Nadia Raquel Benzaquén, Priscila Serravalle, Ana Karina Long, Virginia Ferreira, Agostina Benitez, Luisina Zunino, Camila Lizarraga et al. · 2021 · Revista Panamericana de Salud Pública
11. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic
    Shuchi Anand, Maria E. Montez‐Rath, Jialin Han, LinaCel Cadden, Patti Hunsader, RUSSELL L. KERSCHMANN, Paul Beyer, Scott Dexter Boyd, Pablo García, Mary O. Dittrich et al. · 2021 · JAMA Network Open
12. The dynamics of quantitative SARS‐CoV‐2 antispike IgG response to BNT162b2 vaccination
    Shun Kaneko, Masayuki Kurosaki, Toru Sugiyama, Yuka Takahashi, Yoshimi Yamaguchi, Masayuki Nagasawa, Namiki Izumi · 2021 · Journal of Medical Virology
13. Prime-Boost Vaccination With BNT162b2 Induces High Neutralizing Activity Against SARS-CoV-2 Variants in Naïve and COVID-19-Convalescent Individuals
    Joanna Luczkowiak, Nuria Labiod, Gonzalo Alonso Rivas, Marta Rolo, Fátima Lasala, Jaime Lora‐Tamayo, Mikel Mancheño‐Losa, David Rial, Alfredo Pérez‐Rivilla, María Dolores Folgueira et al. · 2021 · Open Forum Infectious Diseases
14. Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
    Karolina Pieniawska‐Śmiech, Anna Kuraszewicz, Joanna Sado, Karol Śmiech, Aleksandra Lewandowicz‐Uszyńska · 2021 · Journal of Clinical Medicine
15. Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
    Xiabing Lyu, Shota Imai, Tomoyoshi Yamano, Rikinari Hanayama · 2022 · Pharmaceutical Research
16. Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians
    Abdulfattah Adekunle Onifade, Adeola Fowotade, Sheu Kadiri Rahamon, Victory Fabian Edem, Surajudeen Adebayo Yaqub, Olatunji K. Akande, Olatunbosun Ganiyu Arinola · 2023 · PLoS ONE
17. SARS-CoV-2–specific antibody and T-cell immunity in convalescents after infection wave in Beijing in late 2022
    Xuejiao Guan, Qi Huang, Mei Dong, Maozhong Li, Hui Xie, Xiaofeng Wei, Lu Kang, Xue Wang, Aihua Li, Qing Wang et al. · 2023 · Journal of Infection
18. Performance Characteristics of High-Throughput Serologic Assays for Severe Acute Respiratory Syndrome Coronavirus 2 with Food and Drug Administration Emergency Use Authorization
    Elitza S. Theel · 2021 · Clinics in Laboratory Medicine
19. Persistence of Robust Humoral Immune Response in Coronavirus Disease 2019 Convalescent Individuals Over 12 Months After Infection
    Kei Miyakawa, Sousuke Kubo, Sundararaj Stanleyraj Jeremiah, Hirofumi Go, Yutaro Yamaoka, Norihisa Ohtake, Hideaki Kato, Satoshi Ikeda, Takahiro Mihara, Ikuro Matsuba et al. · 2021 · Open Forum Infectious Diseases
20. Longitudinal immune profiling reveals dominant epitopes mediating long-term humoral immunity in COVID-19–convalescent individuals
    Li Min, Jiaojiao Liu, Renfei Lu, Yuchao Zhang, Meng Du, Man Xing, Zhenchuan Wu, Xiangyin Kong, Yufei Zhu, Xianchao Zhou et al. · 2022 · Journal of Allergy and Clinical Immunology
21. SARS-CoV-2 BNT162b2 vaccine–induced humoral response and reactogenicity in individuals with prior COVID-19 disease
    Steven G. Kelsen, Alan S. Braverman, Mark O. Aksoy, Jacob A. Hayman, Puja S. Patel, Charu Rajput, Huaqing Zhao, Susan Gross Fisher, Michael R. Ruggieri, Nina Gentile · 2022 · JCI Insight
22. The kinetics and predictors of anti‐SARS‐CoV‐2 antibodies up to 8 months after symptomatic COVID‐19: A Czech cross‐sectional study
    Ladislav Štěpánek, Magdaléna Janošíková, Lubomír Štěpánek, Marie Nakládalová, Alena Boriková · 2022 · Journal of Medical Virology
23. Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas
    Abdouramane Traoré, Merepen A. Guindo, Drissa S Konate, Bourama Traoré, Seidina A. S. Diakité, Salimata Kanté, Assitan Dembélé, Abdourhamane Cissé, Nathan C. Incandela, Mamoudou Kodio et al. · 2022 · Frontiers in Immunology
24. Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on “Pseudovirus-like” Nanoparticles
    Hanmant K. Gaikwad, Yue Li, Guankui Wang, Ronghui Li, Shaodong Dai, Cody Rester, Ross M. Kedl, Laura M. Saba, Nirmal K. Banda, Robert I. Scheinman et al. · 2022 · ACS Nano
25. Maintaining immunological memory to the SARS-CoV-2 virus during COVID-19 pandemic
    А. П. Топтыгина, Zulfiia E. Afridonova, Закиров Рустам Шакирович, Elena L. Semikina · 2023 · Russian Journal of Infection and Immunity
26. Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity
    Constantin J. Thieme, Mohamed Abou‐El‐Enein, Enrico Fritsche, Moritz Anft, Krystallenia Paniskaki, Sarah Skrzypczyk, Adrian Doevelaar, Magdi Elsallab, Nicola R. Brindle, Arturo Blazquez‐Navarro et al. · 2021 · Allergy
27. Corona Virus Disease-19 serology, inflammatory markers, hospitalizations, case finding, and aging
    Ernst J. Schaefer, Florence Comite, Latha Dulipsingh, Maxine Lang, Jessica Jimison, Martin M. Grajower, Nathan E. Lebowitz, Andrew S. Geller, Margaret R. Diffenderfer, Lihong He et al. · 2021 · PLoS ONE
28. Disparity between levels of anti-RBD IgG and anti-nucleocapsid protein IgG antibodies in COVID-19–recovered patients who received a kidney transplant
    Chih‐Chao Chang, George Vlad, Elena Rodica Vasilescu, Syed Ali Husain, Ya Nan Liu, Wei‐Zen Sun, Ming‐Fu Chang, Nicole Suciu‐Foca, Sumit Mohan · 2021 · Kidney International
29. Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time
    Lauren E. Gentles, Leanne Kehoe, Katharine H. D. Crawford, K. Lacombe, Jane A Dickerson, C. Wolf, Joanna Yuan, Susanna L Schuler, J. Watson, Sankan W. Nyanseor et al. · 2022 · medRxiv
30. Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
    Aljawharah Alrubayyi, Ester Gea‐Mallorquí, Emma Touizer, Dan Hameiri‐Bowen, Jakub T. Kopycinski, Bethany G. Charlton, Natasha Fisher-Pearson, Luke Muir, Annachiara Rosa, Chloë Roustan et al. · 2021 · Research Square
31. Persistence and decay of neutralizing antibody responses elicited by SARS-CoV-2 infection and hybrid immunity in a Canadian cohort
    Amy Nouanesengsy, Anthony Semesi, Kim Ưng Quách, Danton Ivanochko, Walter Byrne, Matthew K. Hwang, Maria-Rosa La Neve, Matilde Leon‐Ponte, Alice Litosh, Nicole Wisener et al. · 2025 · Microbiology Spectrum
32. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunity and Reinfection
    Jennifer M. Dan, Sanjay R. Mehta · 2021 · Clinical Infectious Diseases
33. Clinical Application of Serologic Testing for Coronavirus Disease 2019 in Contemporary Cardiovascular Practice
    Abdulla A. Damluji, Robert H. Christenson, Christopher R. deFilippi · 2021 · Journal of the American Heart Association
34. Distinct kinetics of immunoglobulin isotypes reveal early diagnosis and disease severity of COVID‐19: A 6‐month follow‐up
    Siyang Yu, Jianghong An, Xuejiao Liao, Haiyan Wang, Fen Ma, Dapeng Li, Aimin Li, Weilong Liu, Siwei Zhang, Mingfeng Liao et al. · 2021 · Clinical and Translational Medicine
35. An evaluation of a FluoroSpot assay as a diagnostic tool to determine SARS-CoV-2 specific T cell responses
    Sara M. Mangsbo, Sebastian Havervall, Ida Laurén, Robin S. Lindsay, August Jernbom Falk, Ulrika Wimmercranz Marking, Martin Lord, Marcus Buggert, Pierre Dönnes, Gustaf Christoffersson et al. · 2021 · PLoS ONE
36. BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents
    Bernd Jahrsdörfer, Dorit Fabricius, Judith A. M. Scholz, Carolin Ludwig, Aline Grempels, Ramin Lotfi, Sixten Körper, Guido Adler, Hubert Schrezenmeier · 2021 · Frontiers in Immunology
37. Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
    Susan L. Uprichard, Amornrat O’Brien, Monika Evdokimova, Cynthia L. Rowe, Cara Joyce, Matthew Hackbart, Yazmin E. Cruz-Pulido, Courtney A. Cohen, Michelle L. Rock, John M. Dye et al. · 2022 · Viruses
38. Long Lasting Cellular Immune Response Induced by mRNA Vaccination: Implication for Prevention Strategies
    Laura Vitiello, Lucia Gatta, Sara Ilari, Stefano Bonassi, Mario Cristina, Filippo Ciatti, Massimo Fini, Stefania Proietti, Patrizia Russo, Carlo Tomino et al. · 2022 · Frontiers in Immunology
39. Host Protective Immunity against Severe Acute Respiratory Coronavirus 2 (SARS-CoV-2) and the COVID-19 Vaccine-Induced Immunity against SARS-CoV-2 and Its Variants
    Rashed Noor · 2022 · Viruses
40. Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
    Fabiola Martel, Juliana Cuervo-Rojas, Juana Ángel, Beatríz Ariza, John Mario González, Carolina Ramı́rez-Santana, Yeny Acosta‐Ampudia, Luisa Fernanda Murcia-Soriano, Norma Montoya, Claudia Cecilia Cardozo-Romero et al. · 2023 · Frontiers in Immunology
41. Anti-S and Anti-N Antibody Responses of COVID-19 Vaccine Recipients
    Abdel-Ellah Al-Shudifat, Mohammad Al‐Tamimi, Rand Dawoud, Mohammad Alkhateeb, Amel Mryyian, Anas Al-Ahmad, Manal Mohammad Abbas, Arwa Qaqish · 2023 · Vaccines
42. Long-term sero-positivity for IgG, sequelae of respiratory symptoms, and abundance of malformed sperms in a patient recovered from severe COVID-19
    Ming-Chao Zhu, Diliang Chen, Ya Zhu, Xu-Sheng Xiong, Yan Ding, Feibo Guo, Min-Gang Zhu, Junyang Zhou · 2021 · European Journal of Clinical Microbiology and Infectious Diseases
43. Endogenously Produced SARS-CoV-2 Specific IgG Antibodies May Have a Limited Impact on Clearing Nasal Shedding of Virus during Primary Infection in Humans
    Shu-Yi Yang, Keith R. Jerome, Alexander L. Greninger, Joshua Tisdell Schiffer, Ashish Goyal · 2021 · Viruses
44. INFECTION-ACQUIRED VERSUS VACCINE-INDUCED IMMUNITY AGAINST COVID-19
    Tsvetelina Veselinova Velikova · 2021 · Central Asian Journal of Medical Hypotheses and Ethics
45. SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020
    Alyson Craigie, Reuben McGregor, Alana L. Whitcombe, Lauren H. Carlton, David Harte, Michelle Sutherland, Matthew F. Parry, Erasmus Smit, Gary N. McAuliffe, James E. Ussher et al. · 2021 · Pathology
46. Methods to Identify Immunogenic Peptides in SARS‐CoV‐2 Spike and Protective Monoclonal Antibodies in COVID‐19 Patients
    Lili Li, Meiling Gao, Jie Li, Shulong Zu, Yanan Wang, Chunfeng Chen, Dingyi Wan, Jing Duan, Roghiyh Aliyari, Jingfeng Wang et al. · 2021 · Small Methods
47. Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era
    Cristina de Albuquerque Possas, Adelaide María de Souza Antunes, Alessandra Moreira de Oliveira, Cristina d’Urso de Souza Mendes, Mateus Pinheiro Ramos, Suzanne de Oliveira Rodrigues Schumacher, Akira Homma · 2021 · Circular Economy and Sustainability
48. Dynamics of SARS-CoV-2-specific antibodies among COVID19 biobank donors in Argentina
    Yesica Longueira, María L. Polo, InViV working group, Gabriela Turk, Natalia Laufer, Biobanco de Enfermedades Infecciosas Colección COVID19 working group · 2021 · Heliyon
49. Longitudinal humoral antibody response to SARS-CoV-2 infection among healthcare workers in a New York City hospital
    Vidya P. Menon, Masood A Shariff, Victor A Perez-Gutierrez, Juan Manuel Carreño, Bo Yu, Muzamil Jawed, Marcia Gossai, Elisenda Valdez, Anjana Pillai, Usha Venugopal et al. · 2021 · BMJ Open
50. Humoral immune response to SARS-CoV-2 in five different groups of individuals at different environmental and professional risk of infection
    Silvia Novello, Massimo Terzolo, Paola Berchialla, Martina Gianetta, Valentina Bianco, Francesca Arizio, Dalila Brero, Anna Maria Elena Perini, Adriana Boccuzzi, Valeria Caramello et al. · 2021 · Scientific Reports
51. Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays
    Ingrid Sander, Sabine Kespohl, Eva Zahradnik, Philipp Göcke, Ingolf Hosbach, Burkhard Lorenz Herrmann, Thomas Brüning, Monika Raulf · 2022 · Clinical & Translational Immunology
52. COVID-19 IgG/IgM patterns, early IL-6 elevation and long-term radiological sequelae in 75 patients hospitalized due to interstitial pneumonia followed up from 3 to 12 months
    Domenico Maurizio Toraldo, Francesco Satriano, Rodolfo Rollo, Gabriella Verdastro, Giovanni Imbriani, Emanuele Rizzo, Alberto Argentiero, Andrea Falco, Paolo Ambrosino, Alessandro Miani et al. · 2022 · PLoS ONE
53. Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting
    Kirsty McCance, Helen M. Wise, Jennifer Simpson, Becky Batchelor, Harriet Hale, Lindsay McDonald, Azul Zorzoli, Elizabeth Furrie, Charu Chopra, Frauke Muecksch et al. · 2022 · PLoS ONE
54. SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study
    Eleanor L. Parker, Jordan Thomas, Kelly J. Roper, Samreen Ijaz, Tansy Edwards, Federica Marchesin, Ksenia Katsanovskaja, Lauren Lett, Christopher Jones, Hayley E. Hardwick et al. · 2023 · Frontiers in Immunology
55. 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern
    Melissa García‐Vega, Edgar Alonso Melgoza-González, Sofía Hernández‐Valenzuela, Diana Hinojosa‐Trujillo, Mónica Reséndiz‐Sandoval, Mara Anaís Llamas-Covarrubias, Martín Loza-López, Olivia Valenzuela, Alan Soto‐Gaxiola, Miguel Ángel Hernández‐Oñate et al. · 2023 · iScience
56. University Operations During a Pandemic: A Flexible Decision Analysis Toolkit
    Himanshu Kharkwal, Dakota Olson, Jiali Huang, Abhiraj Mohan, Ankur Mani, Jaideep Srivastava · 2021 · ACM Transactions on Management Information Systems
57. An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2
    Xiangzheng Gao, Keying Liang, Shengsheng Mei, Shanshan Peng, Eu Gene Vong, Jinbiao Zhan · 2021 · Protein Expression and Purification
58. Prevalence of SARS-CoV-2 antibodies in healthy blood donors from the state of Tyrol, Austria, in summer 2020
    Anita Siller, Gregor A. Wachter, Sabrina Barbara Neururer, Bernhard Erich Pfeifer, Manfred Astl, Wegene Borena, Janine Kimpel, Sebastian Elmer, Franziska Spöck, Anja Vales et al. · 2021 · Wiener klinische Wochenschrift
59. Long‐term SARS‐CoV‐2‐specific and cross‐reactive cellular immune responses correlate with humoral responses, disease severity, and symptomatology
    Ida Laurén, Sebastian Havervall, Henry Ng, Martin Lord, Aleksandra Pettke, Nina Greilert‐Norin, Lena Gabrielsson, Aikaterini Chourlia, Catarina Amoêdo‐Leite, Vijay Sai Josyula et al. · 2022 · Immunity Inflammation and Disease
60. High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020–2021
    Timothée Dub, Anna Solastie, Lotta Hagberg, Oona Liedes, Hanna Nohynek, Anu Haveri, Camilla Virta, Saimi Vara, Mervi Lasander, Nina Ekström et al. · 2022 · Frontiers in Medicine
61. Symptoms of COVID-19 infection and magnitude of antibody response in a large community-based study
    Thomas W. McDade, Joshua M. Schrock, Richard T. D’Aquila, Brian S. Mustanski, Nanette Benbow, Lauren A. Vaught, Nina L. Reiser, Matt E. Velez, Ryan R. Hsieh, Daniel T. Ryan et al. · 2021 · medRxiv
62. Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations
    Kevin P. Bliden, Tiancheng Liu, Deepika Sreedhar, Jessica Kost, Jessica Hsiung, Su Zhao, Dingying Shan, Abira Usman, Naval Walia, Alastair Cho et al. · 2021 · medRxiv
63. Live attenuated SARS-CoV-2 vaccine OTS-228 demonstrates efficacy, safety, and stability in preclinical model
    Tobias Britzke, Nico Joël Halwe, Lorenz Ulrich, Angele Breithaupt, G. Tuba Barut, Claudia Wylezich, Nadine Ebert, Bettina Salome Trüeb, Volker Thiel, Donata Hoffmann et al. · 2025 · npj Vaccines
64. Intra-host SARS-CoV-2 diversity in immunocompromised people living with HIV provides insight into the evolutionary trajectory of SARS-CoV-2
    Rageema Joseph, Gert J.K. Marais, Arash Iranzadeh, Arghavan Alisoltani, Diana Ruth Hardie, Mary‐Ann Davies, Alexa Heekes, N. Chetty, Venessa Timmerman, Marvin Hsiao et al. · 2025 · Journal of Virology
65. Natural SARS-CoV-2 infection results in higher neutralization response against variants of concern compared with 2-dose BNT162b2 vaccination in kidney transplant recipients
    Louise Benning, Christian P. Morath, Marie Bartenschlager, Marvin Reineke, Maximilian Töllner, Christian Nußhag, Florian Kälble, Paula Reichel, Matthias Schaier, Paul Schnitzler et al. · 2021 · Kidney International
66. Applications of SARS-CoV-2 serological testing: impact of test performance, sample matrices, and patient characteristics
    Chun Yiu Jordan Fung, Mackenzie Scott, Jordan P. Lerner‐Ellis, Jennifer Taher · 2023 · Critical Reviews in Clinical Laboratory Sciences
67. Performance of plant-produced RBDs as SARS-CoV-2 diagnostic reagents: a tale of two plant platforms
    Mattia Santoni, Noemi Gutierrez-Valdes, Denise Pivotto, Elena Zanichelli, Anthony Rosa, Guillermo Sobrino‐Mengual, Juliette Balieu, Patrice Lerouge, Muriel Bardor, Riccardo Cecchetto et al. · 2024 · Frontiers in Plant Science
68. COVID-19 vaccination: an attempt to control the pandemic
    Sabiha Armin, Anisa Wakil, James A. Tarbox, KENNETH C IWUJI · 2021 · The Southwest Respiratory and Critical Care Chronicles
69. Waning antibodies to SARS-CoV-2 – Don't panic
    Benjamin Meyer · 2021 · The Lancet Regional Health - Europe
70. Qualifying coronavirus disease 2019 convalescent plasma donors in Israel
    Marina Izak, Veronica Gendelman, Sharron Bransburg‐Zabary, Evgeniy Stoyanov, Roni Gat, Dani Cohen, Jacob Chen, ‪Yasmin Maor‬‏, Avi Benov, Boaz I. Lev et al. · 2021 · Vox Sanguinis
71. SAR-CoV-2 infection, emerging new variants and the role of activation induced cytidine deaminase (AID) in lasting immunity
    Asad Ullah, Neelam Mabood, Muhammad Maqbool, Luqman Khan, Maria Ahmad Khan, Mujib Ullah · 2021 · Saudi Pharmaceutical Journal
72. Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection
    Alpaslan Türkkan, Imran Saglik, Cansu Arslan Turan, Ahmet Sahin, Halis Akalin, Beyza Ener, Ateş Kara, Solmaz Celebi, Emre Sahin, Mustafa Kemal HACIMUSTAFAOĞLU · 2022 · Irish Journal of Medical Science (1971 -)
73. Insights into the immune responses of SARS-CoV-2 in relation to COVID-19 vaccines
    Heedo Park, Mee Sook Park, Jong Hyeon Seok, Jaehwan You, Jeonghun Kim, Jeonghun Kim, Man‐Seong Park · 2022 · The Journal of Microbiology
74. Comparison of BNT162b2-, mRNA-1273- and Ad26.COV2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants
    Nigam H. Padhiar, Jin‐Biao Liu, Xu Wang, Xiaolong Wang, Brittany H. Bodnar, Shazheb Khan, Peng Wang, Adil I. Khan, Jin Jun Luo, Wenhui Hu et al. · 2022 · Vaccines
75. An evaluation of 4 commercial assays for the detection of SARS-CoV-2 antibodies in a predominantly mildly symptomatic low prevalence Australian population
    Michael C. Wehrhahn, S. J. Brown, James P. Newcombe, Smathi Chong, J. Evans, M. Figtree, Laurence Hainke, L. Hueston, Sadid F. Khan, E. Marland et al. · 2021 · Journal of Clinical Virology
76. Durable Antibody Responses in Staff at Two Long-Term Care Facilities, during and Post SARS-CoV-2 Outbreaks
    Emily N. Gallichotte, Mary Nehring, Michael C. Young, Sierra Pugh, Nicole R. Sexton, Emily A. Fitzmeyer, Kendra M. Quicke, Megan Richardson, Kristy L. Pabilonia, Nicole P. Ehrhart et al. · 2021 · Microbiology Spectrum
77. Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
    Jer‐Hwa Chang, Jeng‐Fong Chiou, Ching-Sheng Hung, Ming-Che James Liu, Hui‐Wen Chang, Shiao‐Ya Hong, Cheng-Yi Wang, Yi‐Ling Lin, Yi‐Chen Hsieh, Chi‐Li Chung et al. · 2022 · Vaccines
78. The β-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19
    Carla Usai, Joseph M. Gibbons, Corinna Pade, Wenhao Li, Sabina R. M. Jacobs, Áine McKnight, Patrick T.F. Kennedy, Upkar S. Gill · 2022 · Frontiers in Immunology
79. Longitudinal kinetics of RBD+ antibodies in COVID-19 recovered patients over 14 months
    Tsuf Eyran, Anna Vaisman‐Mentesh, David Taussig, Yael Dror, Ligal Aizik, Aya Kigel, Shai Rosenstein, Yael Bahar, Dor Ini, Ran Tur‐Kaspa et al. · 2022 · PLoS Pathogens
80. Persistence of Anti-SARS-CoV-2 Antibodies Six Months after Infection in an Outbreak with Five Hundred COVID-19 Cases in Borriana (Spain): A Prospective Cohort Study
    Salvador Domènech-Montoliu, Joan Puig‐Barberà, María Rosario Pac-Sa, Paula Vidal-Utrillas, Marta Latorre-Poveda, Alba Del Rio-González, Sara Ferrando-Rubert, Gema Ferrer-Abad, Manuel Sanchéz-Urbano, Laura Aparisi-Esteve et al. · 2021 · COVID
81. Optimising social mixing strategies to mitigate the impact of COVID-19 in six European countries: a mathematical modelling study
    Romain R. Ragonnet, Guillaume Briffoteaux, Bridget M Williams, Julian Savulescu, Matthew Segal, Milinda Abayawardana, Rosalind M. Eggo, Daniel Tuyttens, Nouredine Melab, Ben J. Marais et al. · 2020 · medRxiv
82. Systematic review and meta-analysis of COVID-19 vaccines safety, tolerability, and efficacy among HIV-infected patients
    Jacques Lukenze Tamuzi, Ley Muyaya Muyaya, Amal Krishna Mitra, Peter Suwirakwenda Nyasulu · 2022 · medRxiv
83. Severe Acute Respiratory Syndrome Coronavirus‐2
    Patricia R. Slev · 2024 · Wiley eBooks
84. Persistent SARS-CoV-2 positivity
    Annachiara Ferrari, Gaetano Alfano, Giovanni Guaraldi · 2021 · Infectious Diseases in Clinical Practice
85. COVID-19 Case Rates in the UK: Modelling Uncertainties as Lockdown Lifts
    Claire F. Brereton, Matteo Pedercini · 2021 · Systems
86. Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer
    Andrew Cameron, Jessica L. Bohrhunter, Claire A. Porterfield, Rupinder K. Mangat, Michael H. Karasick, Zachary Pearson, Stephen V. Angeloni, Nicole Pecora · 2022 · Microbiology Spectrum
87. Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?
    Ertan Kara, Ferdi Tanır, Hakan Demırhındı, Burak Mete, Filiz Kibar, Sali̇h Çeti̇ner, Aslıhan Candevir, Ayşe İnaltekin · 2022 · Mikrobiyoloji Bulteni
88. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity
    Koos P J van Dam, Adriaan Volkers, Luuk Wieske, Eileen W Stalman, Laura Y. L. Kummer, Zoé L. E. van Kempen, Joep Killestein, Sander W. Tas, Laura Boekel, Gertjan Wolbink et al. · 2023 · BMC Infectious Diseases
89. Post COVID-19 vaccination binding and neutralizing antibody with or without previous infection: An 18-month longitudinal study in Indonesia
    Tonang Dwi Ardyanto, Khariri Khariri, Telly Purnamasari Agus, Amin Subandrio · 2024 · Narra J
90. The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic
    Sudeh Izadmehr, Dara Lundon, Nihal Mohamed, Andrew Katims, Vaibhav G. Patel, Benjamin M. Eilender, Reza Mehrazin, Ketan K. Badani, John P. Sfakianos, Che‐Kai Tsao et al. · 2021 · Frontiers in Oncology
91. Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19
    Maggie L. Bartlett, San Suwanmanee, Nadine Peart Akindele, Shristi Ghimire, Andy Kwan Pui Chan, Chenxu Guo, Stephen J. Gould, Andrea L. Cox, Diane E. Griffin · 2022 · Viral Immunology
92. A quick scoping review of the first year of vaccination against the COVID-19 pandemic: Do we need more shots or time?
    Ayman Ahmed El-Menyar, Naushad Ahmad Khan, Ahammed Abdulla Mekkodathil, Sandro Baleotti Rizoli, Rafael J. Consunji, Eman Elmenyar, Sagar C. Galwankar, Hassan Ali Saoud Al-Thani · 2022 · Medicine
93. A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay
    Benjamín L. Sievers, Terri Gelbart, Gene S. Tan · 2022 · STAR Protocols
94. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines
    Jing Wang, Lei Huang, Nan Guo, Yaping Yao, Chao Zhang, Ruonan Xu, Yan‐Mei Jiao, Ya-Qun Li, Yao-Ru Song, Fu‐Sheng Wang et al. · 2023 · Viruses
95. Reduced Serological Response to COVID-19 Booster Vaccine is Associated with Reduced B Cell Memory in Patients With Inflammatory Bowel Disease; VARIATION [VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON]
    Jayne Doherty, Neil Robert O’Morain, Róisín Stack, Miriam Tosetto, Rosanna Inzitiari, Sophie R O’Reilly, Lili Gu, Juliette Sheridan, Garret J. Cullen, Edel Mc Dermott et al. · 2023 · Journal of Crohn s and Colitis
96. Evaluation of humoral immune response in relation to COVID-19 severity over 1 year post-infection: critical cases higher humoral immune response than mild cases
    Mi-Seon Bang, Choon‐Mee Kim, Nam‐Hyuk Cho, Jun-Won Seo, Da Young Kim, Na Ra Yun, Dong‐Min Kim · 2023 · Frontiers in Immunology
97. SARS-CoV-2 in Mexico: Beyond Detection Methods, Scope and Limitations
    Cynthia Martinez-Liu, Natalia Martínez-Acuña, Daniel Arellanos-Soto, Kame A. Galán-Huerta, Sonia Amelia Lozano-Sepúlveda, María del Carmen Martínez-Guzmán, Ana María Rivas-Estilla · 2021 · Diagnostics
98. Serological Profile of Children and Young Adults with at Least One SARS-CoV-2 Positive Cohabitant: An Observational Study
    Marco Farronato, Carolina Dolci, Elisa Boccalari, Sara Izadi, Luis Hernan Salvatierra Rios, Maurizio Festa, Valentina Panetta, Danila De Vito, Gianluca Martino Tartaglia · 2021 · International Journal of Environmental Research and Public Health
99. Comprehensive Characterization of COVID-19 Patients with Repeatedly Positive SARS-CoV-2 Tests Using a Large U.S. Electronic Health Record Database
    Xiao Dong, Yujia Zhou, Xiao‐Ou Shu, Elmer Victor Bernstam, Rebecca A. Stern, David Michael Aronoff, Hua Xu, Loren P. Lipworth · 2021 · Microbiology Spectrum
100. Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review)
     N. A. Lyubavina, С. Г. Сальцев, Меньков Николай Викторович, Тюрикова Любовь Валерьевна, С. С. Пластинина, Шония Моника Левановна, ALEXANDER A. TULICHEV, Милютина Марина Юрьевна, Е. В. Макарова · 2021 · Современные технологии в медицине